← Back to Clinical Trials
Recruiting NCT06573853

Outcomes of PFA Vs. RFA for Patients with PSVT: a Retrospective and Propensity Score Matching Study

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Paroxysmal Supraventricular Tachycardia
Sponsor Caijie Shen
Study Type OBSERVATIONAL
Phase N/A
Enrollment 428
Sex ALL
Min Age 18 Years
Max Age 80 Years
Start Date 2022-10-11
Completion 2025-06-30
Interventions
Focal Pulsed Field Ablation (PFA)Focal Radiofrequecy Ablation (RFA)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this retrospective study is to compare the long-term follow-up outcomes of pulses field ablation (PFA) Vs. radiofrequency ablation (RFA) for the patients with paroxysmal supraventricular tachycardia (PSVT). The main question to answer is: Does the PFA was more effecient and safer that RFA for treatment of PSVT during procedure and after 1-year follow-up? Researchers will compare the acute and long-term efficiency and safety between PFA and RFA. 1. Recieved PFA or RFA 1 year ago 2. Finish the visit to the clinic at 1, 3, 6, 12 months for examinations and blood testings 3. Patients recieved PFA and PFA under propensity matched comparison according to differen variety of PSVT

Eligibility Criteria

Inclusion Criteria: 1. Patients with symptomatic PSVT including: atrioventricular nodal re-entrant tachycardia (AVNRT), atrioventricular re-entrant tachycardia (AVRT); 2. Age range: 18 years old ≤ age ≤ 80 years old, with no gender restriction; 3. Willing to receive the examinations and testings during one year follow-up required by the protocol; 4. Voluntary signed informed consent. Exclusion Criteria: 1. Organic heart disease; 2. History of cardiac surgery; 3. Previous failed ablation of PSVT; 4. Presence of any implants, such as a permanent pacemaker; 5. Patients with invasive systemic infections or advanced malignant tumors; 6. Contraindications for septal puncture or retrograde transaortic access surgery; 7. Any condition that makes the use of heparin or aspirin inappropriate; 8. Pregnant or lactating women; 9. Inability to fully comply with the study procedures and follow-ups or to provide their own informed consent; 10. Coexistence with other arrhythmias, such as atrial fibrilla

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}